XORTX Therapeutics Inc
XRTX0.625USD
-0.014-2.13%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
2.37MMarket Cap
LossP/E TTM
More Details of XORTX Therapeutics Inc Company
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
XORTX Therapeutics Inc Info
Ticker SymbolXRTX
Company nameXORTX Therapeutics Inc
IPO dateSep 30, 2015
CEODr. Allen W. Davidoff, Ph.D.
Number of employees2
Security typeOrdinary Share
Fiscal year-endSep 30
Address3710 - 33rd Street NW
CityCALGARY
Stock exchangeTSX Venture Exchange (former Canadian Ventures Exchange)
CountryCanada
Postal codeT2L 2M1
Phone14034557727
Websitehttps://www.xortx.com/
Ticker SymbolXRTX
IPO dateSep 30, 2015
CEODr. Allen W. Davidoff, Ph.D.
Company Executives of XORTX Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James Neville (Jim) Fairbairn, CPA
Mr. James Neville (Jim) Fairbairn, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James Neville (Jim) Fairbairn, CPA
Mr. James Neville (Jim) Fairbairn, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Oct 30
Updated: Thu, Oct 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
10.98%
Davidoff, Allen Warren
2.31%
Citadel Advisors LLC
0.74%
UBS Financial Services, Inc.
0.40%
Giovinazzo (Anthony)
0.18%
Other
85.38%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
10.98%
Davidoff, Allen Warren
2.31%
Citadel Advisors LLC
0.74%
UBS Financial Services, Inc.
0.40%
Giovinazzo (Anthony)
0.18%
Other
85.38%
Shareholder Types
Shareholders
Proportion
Corporation
10.98%
Individual Investor
2.50%
Hedge Fund
0.74%
Investment Advisor
0.40%
Bank and Trust
0.08%
Other
85.30%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
15
63.97K
1.23%
-645.66K
2025Q2
17
129.44K
3.30%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
2023Q3
20
176.53K
8.83%
-185.14K
2023Q2
19
179.60K
8.98%
-178.94K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Davidoff, Allen Warren
120.45K
2.31%
+8.19K
+7.30%
Jul 22, 2025
Citadel Advisors LLC
38.47K
0.74%
+38.47K
--
Jun 30, 2025
UBS Financial Services, Inc.
20.79K
0.4%
+20.79K
--
Jun 30, 2025
Giovinazzo (Anthony)
9.63K
0.18%
--
--
Apr 30, 2025
National Bank of Canada
3.93K
0.08%
+3.76K
+2160.92%
Jun 30, 2025
Raymond James & Associates, Inc.
500.00
0.01%
+500.00
--
Jun 30, 2025
Van Damme (Paul Joseph)
7.11K
0.14%
--
--
Apr 30, 2025
Clearstead Advisors LLC
277.00
0.01%
--
--
Jun 30, 2025
Spartan Fund Management Inc.
--
0%
-119.30K
-100.00%
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Date
Type
Ratio
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
